1. Home
  2. AVXL vs CTLP Comparison

AVXL vs CTLP Comparison

Compare AVXL & CTLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVXL
  • CTLP
  • Stock Information
  • Founded
  • AVXL 2001
  • CTLP 1992
  • Country
  • AVXL United States
  • CTLP United States
  • Employees
  • AVXL N/A
  • CTLP N/A
  • Industry
  • AVXL Biotechnology: Biological Products (No Diagnostic Substances)
  • CTLP EDP Services
  • Sector
  • AVXL Health Care
  • CTLP Technology
  • Exchange
  • AVXL Nasdaq
  • CTLP Nasdaq
  • Market Cap
  • AVXL 779.5M
  • CTLP 670.7M
  • IPO Year
  • AVXL N/A
  • CTLP N/A
  • Fundamental
  • Price
  • AVXL $8.35
  • CTLP $10.55
  • Analyst Decision
  • AVXL Strong Buy
  • CTLP Strong Buy
  • Analyst Count
  • AVXL 2
  • CTLP 4
  • Target Price
  • AVXL $44.00
  • CTLP $12.00
  • AVG Volume (30 Days)
  • AVXL 995.5K
  • CTLP 442.3K
  • Earning Date
  • AVXL 02-12-2025
  • CTLP 02-06-2025
  • Dividend Yield
  • AVXL N/A
  • CTLP N/A
  • EPS Growth
  • AVXL N/A
  • CTLP N/A
  • EPS
  • AVXL N/A
  • CTLP 0.19
  • Revenue
  • AVXL N/A
  • CTLP $285,112,000.00
  • Revenue This Year
  • AVXL N/A
  • CTLP $18.75
  • Revenue Next Year
  • AVXL N/A
  • CTLP $14.91
  • P/E Ratio
  • AVXL N/A
  • CTLP $56.72
  • Revenue Growth
  • AVXL N/A
  • CTLP 12.88
  • 52 Week Low
  • AVXL $3.25
  • CTLP $5.75
  • 52 Week High
  • AVXL $14.44
  • CTLP $11.16
  • Technical
  • Relative Strength Index (RSI)
  • AVXL 40.39
  • CTLP 63.07
  • Support Level
  • AVXL $8.50
  • CTLP $10.60
  • Resistance Level
  • AVXL $9.20
  • CTLP $11.16
  • Average True Range (ATR)
  • AVXL 0.49
  • CTLP 0.49
  • MACD
  • AVXL -0.01
  • CTLP 0.17
  • Stochastic Oscillator
  • AVXL 32.23
  • CTLP 81.29

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

About CTLP Cantaloupe Inc.

Cantaloupe Inc operates in the small ticket electronic payments industry. It provides wireless, cashless, micro-transactions, and networking services within the unattended Point of Sale (POS) market. Its products and services portfolio consists of ePort Cashless devices, eSuds, EnergyMisers, and Value-added services which include Loyalty and Prepaid, Intelligent Vending, and others. The company offers services to different industries covering car wash, taxi and transportation, laundry, vending, kiosk, amusement, and arcade. The company derives revenue from the sale or lease of equipment and services to the small ticket, unattended POS market, and the majority of its revenue is derived from subscription and transaction fees.

Share on Social Networks: